Insider Selling: Fennec Pharmaceuticals (TSE:FRX) Insider Sells C$1,061,087.30 in Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Southpoint Capital Advisors Lp sold 85,918 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of C$12.35, for a total transaction of C$1,061,087.30. Following the transaction, the insider owned 3,764,082 shares in the company, valued at C$46,486,412.70. This represents a 2.23% decrease in their ownership of the stock.

Southpoint Capital Advisors Lp also recently made the following trade(s):

• On Friday, November 14th, Southpoint Capital Advisors Lp sold 160,100 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$11.24, for a total value of C$1,799,524.00.
• On Tuesday, October 7th, Southpoint Capital Advisors Lp sold 26,900 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of C$13.23, for a total value of C$355,887.00.
• On Wednesday, October 8th, Southpoint Capital Advisors Lp sold 19,605 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$13.07, for a total value of C$256,237.35.
• On Thursday, October 9th, Southpoint Capital Advisors Lp sold 20,609 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of C$12.89, for a total value of C$265,650.01.

Fennec Pharmaceuticals Stock Performance

Shares of TSE FRX opened at C$10.60 on Tuesday. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83. The company has a market capitalization of C$362.02 million, a P/E ratio of -40.77 and a beta of 2.51. Fennec Pharmaceuticals Inc. has a 12 month low of C$7.02 and a 12 month high of C$13.83. The stock has a 50 day moving average of C$11.55 and a 200-day moving average of C$11.73.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.